|
|
Where Small Cap Stocks Thrive Since
1999
Cardiome
Pharma Corp. (CRME) Website:
www.Cardiome.com " Product
Focused Drug Development Company."
BRINAVESS
(vernakalant) for Infusion Approved in the European Union for Rapid
Conversion of Recent Onset Atrial Fibrillation
Merck and Cardiome Pharma Corp. announced
that the intravenous formulation of BRINAVESS (vernakalant) has been granted
marketing approval in the European Union, Iceland and Norway for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in adults:
for non-surgery patients with AF of seven days or less and for post-cardiac
surgery patients with AF of three days or less.
Overview Cardiome Pharma Corp.
(CRME) is a product-focused drug development company dedicated to
the advancement and commercialization of novel treatments for disorders of
the heart and circulatory system. The Company's product
pipeline primarily includes Vernakalant, which just successfully completed
Phase III (ACT 5) clinical trials for the treatment of atrial fibrillation;
Vernakalant (oral) that completed Phase IIa clinical trials and Phase IIb
clinical trials for the treatment of atrial fibrillation; and GED-aPC, which
completed Phase I clinical trials for the treatment of multiple disease
states. It has collaboration and
license agreements with Merck & Co., for the development and
commercialization of vernakalant; and Astellas Pharma US, Inc. to develop,
make, and sell injectable formulations of vernakalant in North
America. CRME
Investor Highlights Announced
that the intravenous formulation of BRINAVESS has been granted marketing
approval in the European Union, Iceland and Norway for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Recorded net income of $4.6
million ($0.08 per common share)
for the three months ended June 30, 2010.
Total revenue for Q2-2010
was $12.4 million, an increase of $5.1
million from $7.3 million in
Q2-2009.
At June
30, 2010, the Company had cash and cash equivalents of $57.7
million.
Are
You Overlooking Value in Today's Markets... 15
Companies With Zero Debt...
Instead of debt, these 15 companies hold cash and liquid investments in order to
make acquisitions, investments and to run daily operations. SmallCapReview:
Small Caps On The Move... 10
Great Cities For Raising Families... Do
Small Caps Equal Large Profits Now?
Income
For Life... See
how much your nest egg is worth in lifetime monthly payments. Worst-Paying
Jobs For Doctors... 10
Products That Rocked The Market...
Investors have made -- or lost -- millions of dollars betting on the success of
new products, from New Coke to Crocs to the iPod. Any
New Theme Has To Begin Small... Picking
Industries Counts More Than Stock Picks...
Seven
Secrets Of College Admissions... Health
Care Reform: 13 Tax Changes On The Way... Small
Caps Close Best Week Of August... Small
Cap Technology Stocks Are Ripe For Takeover... Consumers
Aren't Spending? Hogwash... Best
Buy, Target Offer Game Trade-Ins... The
10 Highest State Taxes On Capital Gains... Don't
Be Afraid Of All-Time Highs...
Still bullish? Don't let a
stock's high price stop you from buying. Ultra Clean Holdings (UCTT)
"The Proven Resource For Complex Systems Integration," Salix Pharmaceuticals (SLXP)
"Advancing Treatment in Gastroenterology" Micrus Endovascular Corporation (MEND)
"A World Leader in Less-Invasive Neurointerventional Solutions To Treat Cerebral Vascular Disease." Power-One (PWER)
"One Of The World's Ten Largest Providers Of Power Conversion And Management Solutions," Follow Us On
| ||||||||||||
| B |
